Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Melanoma/Skin Cancers

Type: Poster Session

Time: Monday June 3, 1:15 PM to 4:15 PM

Location: Hall A

Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study.

Sub-category:
Advanced Disease

Category:
Melanoma/Skin Cancers

Meeting:
2019 ASCO Annual Meeting

Abstract No:
TPS9596

Poster Board Number:
Poster Session (Board #166a)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr TPS9596)

Author(s): Matteo S. Carlino, Paolo Antonio Ascierto, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean Jacques Grob, Axel Hauschild, John M. Kirkwood, Georgina V. Long, Peter Mohr, Caroline Robert, Merrick I. Ross, Richard A. Scolyer, Vernon K. Sondak, Charles Yoon, Andrew Stewart Poklepovic, Piotr Rutkowski, James R. Anderson, Sama Ahsan, Nageatte Ibrahim, Jason J. Luke; Westmead and Blacktown Hospitals, Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy; Gustave Roussy Cancer Centre and University Paris-Saclay, Paris, France; The University of Texas MD Anderson Cancer Center, Houston, TX; Aix-Marseille University, Marseille, France; Universitats-Hautklinik Kiel, Kiel, Germany; Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia; Elbe Kliniken Buxtehude, Buxtehude, Germany; Gustave Roussy and Paris-Sud University, Villejuif, France; The University of Sydney, Melanoma Institute Australia and Royal Prince Alfred Hospital, Sydney, NSW, Australia; Moffitt Cancer Center, Tampa, FL; Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA; VCU Massey Cancer Center, Richmond, VA; Maria Sklodowska-Curie Institute, Warsaw, Poland; Merck & Co., Inc., Kenilworth, NJ; University of Chicago Comprehensive Cancer Center, Chicago, IL

Abstract Disclosures

Abstract:

Background: Adjuvant pembrolizumab showed significantly longer recurrence-free survival than placebo in patients with resected stage III melanoma in the KEYNOTE-054 study. KEYNOTE-716 (NCT03553836) is a randomized, placebo-controlled, double-blind, multicenter phase 3 study of adjuvant pembrolizumab in patients with surgically resected high-risk stage II melanoma. Methods: Key eligibility criteria are age ≥12 y with newly diagnosed, completely resected stage IIB/IIC cutaneous melanoma, defined by the AJCC Cancer Staging Manual, 8th edition (wide excision and negative sentinel lymph node biopsy with no evidence of distant metastasis). Patients with mucosal or uveal melanoma or prior treatment (including radiation) for melanoma beyond resection of primary disease within 12 wk of the start of study treatment were excluded. In this 2-part study, in the double-blind phase (part 1), patients will be randomly assigned 1:1 to receive pembrolizumab 200 mg for patients ≥18 y or 2 mg/kg for patients ≥12 y to < 18 y (maximum dose, 200 mg) or placebo every 3 wk for 17 cycles. Study treatment will begin within 12 wk of complete resection. Tumor imaging will be performed every 24 wk while treatment is ongoing, at the end of treatment, every 6 mo for the first 3 y off treatment, and then yearly for up to 2 y or until recurrence (up to 5 y of total imaging). Adverse events will be recorded until 30 d after treatment end (90 d for serious AEs) and graded per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. In the unblinded phase (part 2), patients with confirmed recurrence may be rechallenged (patients received pembrolizumab in part 1) or crossed over to pembrolizumab (patients received placebo in part 1). Resected local or distant recurrence or unresectable disease will be treated for an additional 17 or 35 cycles, respectively. Tumor imaging in part 2 will occur every 12 wk during treatment. The primary end point is recurrence-free survival; secondary end points are distant metastasis-free survival, overall survival, and safety. Approximately 954 patients will be enrolled. Clinical trial information: NCT03553836

 
Other Abstracts in this Sub-Category:

 

1. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9500 First Author: Gerald Fogarty
Category: Melanoma/Skin Cancers - Advanced Disease

 

2. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

Meeting: 2019 ASCO Annual Meeting Abstract No: 9501 First Author: Hussein Abdul-Hassan Tawbi
Category: Melanoma/Skin Cancers - Advanced Disease

 

3. Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9505 First Author: Michael Weichenthal
Category: Melanoma/Skin Cancers - Advanced Disease

 

More...